Table 2.
Patient characteristics (N = 67)
| Age, years, median (range) | 79 (60–92) | |
|---|---|---|
| Sex | Male | n = 24 (36 %) |
| Female | n = 43 (64 %) | |
| Stage | IA | n = 52 (78 %) |
| IB-III | n = 15 (22 %) | |
| Location | Left Lower lobe | n = 16 (24 %) |
| Left Upper Lobe | n = 16 (24 %) | |
| Right Lower Lobe | n = 12 (18 %) | |
| Right Upper Lobe | n = 23 (34 %) | |
| Tumor volume | <2.5 cc | n = 17 (25 %) |
| 5-2.5 cc | n = 19 (29 %) | |
| 5-10 cc | n = 7 (11 %) | |
| 10-20 cc | n = 9 (13 %) | |
| >20 cc | n = 15 (22 %) | |
| BED10 a | Mean | 107.8 |
| Median (Range) | 105.6 (180–85.5) | |
| Tracking | XSight-spine | n = 30 (45 %) |
| XSight-lung | n = 3 (5 %) | |
| XSight-spine + Fiducials | n = 34 (50 %) | |
| Histology | Adenocarcinoma | n = 30 (44 %) |
| Squamous Cell Carcinoma | n = 14 (21 %) | |
| Non-small cell lung carcinoma-NOSb | n = 14 (21 %) | |
| Carcinoid | n = 3 (4 %) | |
| Sarcomatoid mesothelioma | n = 1 (2 %) | |
| Non-diagnostic biopsy | n = 6 (8 %) | |
aBiologic Effective Dose, Gy10 or α/β ratio = 10
bNot otherwise specified